ATLANTA—Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information stored in Vanderbilt’s DNA biobank.
COPD is a group of diseases that cause airflow blockage and breathing-related problems. COPD, which includes emphysema and chronic bronchitis, is the third leading cause of death in the United States and has been diagnosed in more than 13 million people, with millions more probably affected. There is no treatment for COPD.
Genome-wide association studies have already identified several genes that contribute to the development of COPD, but scientists still lack a complete understanding of the pathogenesis of this disease. In this study, the researchers examined the link between genetic variants in COPD and clinical phenotypes, or physical characteristics such as disease history, to understand the biological mechanisms underlying COPD.
Using genetic data from patients who participated in BioVU, Vanderbilt’s DNA biobank that is linked to deidentified electronic health records, the researchers performed a phenome-wide association study (PheWAS) of 16 previously reported COPD-associated single nucleotide polymorphisms (SNPs) that were identified from a genome-wide association study. SNPs represent a difference in a single DNA building block, called a nucleotide, and are the most common type of genetic variation among people.
Data were available from 18,335 adults of European descent who had provided informed consent. The researchers identified 1,805 COPD cases. They defined phenotypes by using ICD-9 codes, or unique codes for different symptoms of disease.
“Because there’s no treatment right now for COPD, we’re trying to figure out whether we can diagnose or prognose this disease earlier to prevent it,” said Dr. Xiangming Ji, assistant professor in the Byrdine F. Lewis College of Nursing and Health Professions at Georgia State. “People are genetically very similar, but a major difference is because of this single nucleotide polymorphism (SNP). This could be changed by the environment also. So some people with a specific SNP are more prone to get this disease. We found that a specific SNP, rs2074488, is positively associated with COPD and is linked to the HLA-C gene, which presents a protein to B or T immune cells to kill bacteria or viruses. This makes COPD similar to autoimmune disease.
“This SNP is also associated with several autoimmune diseases, like type 1 diabetes and rheumatoid arthritis, which suggests a genetic link between autoimmune disease and COPD. Many years ago, people believed that one of the causes of COPD is because the autoimmune system attacks its own lungs. We kind of confirmed that by our big data.”
The findings are published in the American Journal of Respiratory Cell and Molecular Biology.
This study could provide insight on opportunities for drug repurposing, Ji said. For instance, a drug that is effective for diabetes could possibly be used to treat COPD because both diseases involve autoimmune responses.
The findings suggest future studies should explore the role of the immune system in the pathogenesis of COPD. The researchers also hope that scientists will investigate how normal SNPs, such as those associated with metabolism pathways or different nutrient receptors, are related to COPD.
Co-authors of the study include Dr. Xinnan Niu, Dr. Jun Qian, Victoria Martucci, Dr. Joshua Denny, Dr. Pierre Massion and Dr. Melina Aldrich of Vanderbilt University Medical Center; Dr. Sarah Pendergrass of Geisenger Health System; Dr. Ivan Gorlov of Dartmouth Geisel School of Medicine; and Dr. Christopher Amos of Baylor College of Medicine.
The study is funded by the National Institutes of Health, Department of Defense and Flight Attendant Medical Research Institute.
To read the study, visit https://www.atsjournals.org/doi/full/10.1165/rcmb.2017-0409LE.
Department of Nutrition
Dr. Ji’s research examines metabolic changes in the airway epithelium from normal cells to at-risk epithelial cells all the way to cancer cells. Dr. Ji is gathering evidence of the critical role metabolic reprogramming plays in the airway epithelial in the development of both COPD and lung cancer. He is currently researching the validation of neutral amino acid transporters to sustain the metabolic reprogramming in COPD and lung cancer.